Rabbit ATLG and thymoglobulin in haploidentical hematopoietic cell transplantation product specific evidence and unresolved dosing with PTCy
Rabbit anti-T-lymphocyte globulin (ATLG; Grafalon) and rabbit anti-thymocyte globulin (ATG; Thymoglobulin) are noninterchangeable polyclonal preparations used within haploidentical hematopoietic cell transplantation (haplo-HCT) platforms. Their immunogens, antibody repertoires and nominal dose scales differ, but direct comparative clinical evidence is sparse. This narrative review examines product-specific evidence, active-antibody exposure and the unresolved dosing of serotherapy combined with post-transplant cyclophosphamide (PTCy). The available propensity-matched haploidentical comparison used Thymoglobulin 6 mg/kg and ATLG 10 mg/kg; the latter was substantially below ATLG totals commonly used even in matched-donor transplantation. Its infection and chronic graft-versus-host disease findings therefore cannot establish intrinsic product differences. PTCy-based and serotherapy-based platforms coexist, including outside Western centers, and neither the optimal rabbit-globulin dose nor the optimal PTCy dose in combined regimens is established. Recipient absolute lymphocyte count (ALC), infusion timing and graft cellularity modify exposure. ATLG-specific ALC studies support this association, but prospectively validated ATLG ALC-based dosing models remain needed. Product, conditioning, graft source, PTCy, mycophenolate mofetil and other immunosuppression should be evaluated as one protocol. Clinical use should follow product-specific, locally validated regimens while trials define exposure targets and the net benefit of combination prophylaxis.
Authors
- Yi Xiao
- Yu Wang
Institutions
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Clinical and Experimental Medicine
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1007/s10238-026-02395-x
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China